<DOC>
	<DOCNO>NCT01661283</DOCNO>
	<brief_summary>To determine clinical response rate everolimus combination bevacizumab patient chemotherapy refractory sporadic neurofibromatosis type 1 ( NF1 ) associate malignant peripheral nerve sheath tumor ( MPNST ) . To evaluate toxicity safety everolimus combination bevacizumab individual MPNST</brief_summary>
	<brief_title>SARC016 : Study Everolimus With Bevacizumab Treat Refractory Malignant Peripheral Nerve Sheath Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients 18 old Unresectable metastatic sporadic NF1 associate highgrade MPNST Experienced progression one prior regimens cytotoxic chemotherapy Patients must able swallow tablet Patients must measurable disease , define least one tumor measurable Patients develop recurrence progression ( WHO criteria ) MPNST previously radiate field may enrol least 4 week since last dose radiation therapy Patients must recover toxic effect prior therapy enter study Adequate organ function ECOG performance status 0 , 1 , 2 Patents receive anthracycline prior enrollment must ejection fraction â‰¥ 50 % Subjects childbearing potential require acceptable form birth control Informed consent Patients currently receive anticancer therapy receive anticancer therapy within 3 week start study drug patient receive prior treatment investigational drug 4 week start study drug Patients may currently receive strong inhibitor CYP3A4 , may receive medication within 1 week entry Prior radiotherapy within 4 week start study drug Patients major surgery significant traumatic injury within 4 week start study drug , Patients recover side effect major surgery Patients may require major surgery course study Less 7 day pass core biopsy minor surgical procedure exclude placement vascular access device Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent ( Topical inhale corticosteroid allow ) Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastases Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin Patients severe and/or uncontrolled medical condition condition could affect participation study Female patient pregnant breast feed Patients receive prior treatment mTOR inhibitor bevacizumab Patients know hypersensitivity rapamycins concurrent use anticoagulant drug Patients use Seville orange , star fruit , grapefruit juice , St. John 's Wort Patients take enzyme inducing anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MPNST</keyword>
	<keyword>malignant peripheral nerve sheath tumor</keyword>
	<keyword>RAD001</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Avastin</keyword>
	<keyword>mTOR inhibitor</keyword>
</DOC>